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Abstract: Mendelian randomization refers to the random allocation of alleles at the time of 
gamete formation. In observational epidemiology, this refers to the use of genetic variants 
to estimate a causal effect between a modifiable risk factor and an outcome of interest. In 
this  review,  we  recall  the  principles  of  a  ―Mendelian  randomization‖  approach  in 
observational epidemiology, which is based on the technique of instrumental variables; we 
provide simulations and an example based on real data to demonstrate its implications; we 
present the results of a systematic search on original articles having used this approach; and 
we discuss some limitations of this approach in view of what has been found so far. 
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1. Introduction  
Observational studies have brought important insight into disease etiology. During the past decade 
however, the validity of observational studies has been questioned [1]. This is due to the fact that the 
role of selected risk, or protective, factors identified via observational studies could not be confirmed 
by subsequent large randomized controlled trials. For instance, hormonal replacement therapy appeared 
to protect women against coronary heart disease in observational studies [2], whereas randomized trials 
showed no such protection [3]. Other examples are given by antioxidant vitamin supplementation [4-6]. 
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One  cannot,  for  ethical  and  technical  reasons,  randomize  risk  factors  using  controlled  trials  in 
humans. The identification of risk factors therefore relies on observational studies, which are prone to 
spurious  results  due  to  confounding  factors,  reverse  causation,  and/or  selection  biases  [7].  As  a 
consequence, it is difficult to firmly establish causal relationships between risk factors and disease. 
Most common diseases (e.g., cancer, cardiovascular disease, etc.) are complex and are influenced by 
multiple risk factors that may be correlated with each other. In this context, each factor is expected to 
have a small influence on disease risk. Epidemiologists have the hard task to determine whether a 
putative risk factor is causally related to a specific disease, independently of all other risk factors. A 
promising approach to help epidemiologists in this task is Mendelian randomization. In this review, we 
first  recall the principles of a  ―Mendelian randomization‖ approach in observational epidemiology 
(Section  2),  we  then  provide  some  technical  explanation  of  the  method  of  instrumental  variable 
(Section 3), followed by simulations and an example with real data (Section 4). We then present the 
results of a systematic search on original articles having used this approach (Section 5), discuss its 
limitations (Section 6) and present concluding remarks (Section 7). 
2. Mendelian Randomization in Observation Epidemiology 
Mendelian randomization refers to the random allocation of alleles at the time of gamete formation. 
A specific genotype carried by a person therefore results from two such randomized transmissions, one 
from  the  paternally  inherited  allele  and  the  other  from  the  maternally  inherited  allele.  A  logical 
consequence of these randomizations is that genotypes are not expected to be associated with known 
(measurable or not) or unknown confounders for any outcome of interest, except those lying on the 
causal  pathway  between  the  genotype  and  the  outcome.  This  should  hence  allow  analyzing  the 
genotype-risk factor association and the genotype-outcome association in an unconfounded manner. By 
combining  appropriately  the  results  of  these  two  analyses,  one  can  get  an  estimate  of  the  risk  
factor-outcome association, which is itself not confounded. This is analogous to randomized controlled 
trials (of sufficient sample size), in which the random allocation of treatment (or preventive measure) 
is expected to lead to an even distribution of (known or unknown) confounding factors across each 
groups. The term ―Mendelian randomization‖ is now frequently used in observational epidemiology to 
refer to the use of genetic variants to estimate a causal effect between a specific modifiable risk factor 
and  a  trait/disease  of  interest.  The  idea  is  to  overcome  some  of  the  problems  encountered  in 
observational epidemiology, such as residual confounding and reverse causation, by taking advantage 
of the natural random allocation of alleles during meiosis [8].  
We here provide an example to illustrate this approach. The aldehyde dehydrogenase 2 (ALDH2) 
gene encodes the enzyme aldehyde dehydrogenase, which catalyzes the chemical transformation from 
acetaldehyde to acetic acid. Carriers of the ALDH2 *2*2 genotype have reduced alcohol consumption 
because  of  adverse  reactions  (facial  flush,  headache,  nausea  and  drowsiness)  due  to  acetaldehyde 
accumulation. This fact has been used to show that alcohol intake increases the risk of esophageal 
cancer [9] or head and neck cancer [10], which is consistent with the findings from observational 
studies.  Whereas  reported  alcohol  consumption  may  be  subject  to  measurement  errors,  ALDH2 
genotypes can be measured accurately, are present since birth, result from the random allocation of the 
paternally  and  maternally  inherited  alleles,  are  strongly  associated  with  alcohol  consumption,  and Int. J. Environ. Res. Public Health 2010, 7                 
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therefore  provide  a  unique  opportunity to  assess, in  an unconfounded manner, the risk of disease 
associated with alcohol consumption. As we shall discuss in Section 6, such an approach - although 
appealing - also raises some methodological issues. 
Historically,  the  first  description  of  the  concept  of  Mendelian  randomization  in  observational 
epidemiology is  attributed to  Katan  [11], who suggested to  use the  APOE  gene to infer causality 
between  cholesterol  and  cancer.  The  concept  was  further  developed  by  Davey  Smith  and  
Ebrahim [7,8,12,13], who have shown that the causal effect of a risk factor (X) on an outcome (Y) can 
be estimated by combining the effects of a genetic variant (Z) on X and on Y, provided that certain 
assumptions  are  met  (see  Figure  1).  Thomas  and  Conti  [14]  have  shown  that  the  Mendelian 
randomization approach was in fact an application of the instrumental variable approach, which had 
been used since more than 70 years by econometricians. Wehby et al. have recently advocated that the 
term ―Mendelian randomization‖ should be replaced by ―instrumental variable analysis with genetic 
instruments‖  [15].  We  tend  to  agree  with  this  latter  statement  after  having  reviewed  the  medical 
literature and observed that the term ―Mendelian randomization‖ was used with different meanings by 
different researchers, which might be confusing.  
Figure  1.  Directed  acyclic  graph  (DAG)  representing  causal  relationships  between  the 
genetic instrument (Z ), the modifiable risk factor (X ), the outcome (Y ) and the (known 
or  unknown,  measurable  or  non-measurable)  confounders  ( U ),  which  satisfy  the 
assumptions  required  by  a  Mendelian  randomization.  In  a  DAG,  a  node  represents  a 
variable and an arrow a direct causal effect. Because a cause must precede an effect, no 
cycle is allowed and this is why the graph is termed acyclic (there is no loop from one node 
back to itself following the arrows). See Greenland et al. [16] for more details on DAG. 
 
3. The Method of Instrumental Variables 
We consider the case where an association between a continuous (or binary) modifiable exposure 
X  and a continuous response Y  is measured via a beta coefficient in a linear regression, defined as the 
average increase in Y  when  X  is increased by one unit (respectively, when changing the category of 
X  if  the  exposure  is  binary).  When  observing  such  an  association  in  epidemiolog ical  research, Int. J. Environ. Res. Public Health 2010, 7                 
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however, it is often difficult to determine which of the two variables ( X  or Y ) is the cause and which 
the effect, or whether a third variable (a confounder, U ) related to both variables is responsible for the 
observed association. Moreover, measurement error could attenuate the beta coefficient. Thus, it is not 
obvious how a significant non-zero (e.g., positive) beta coefficient obtained from a classical (ordinary) 
least  squares  estimate  should  be  interpreted.  Here  are  five  possible  interpretations  (among  
many others): 
1.  The beta coefficient is a consistent estimate of the causal effect of  X  on Y . 
2.  The  beta  coefficient  is  actually  underestimating  the  true  causal  effect  of  X  on Y  
because of measurement error. 
3.  The beta coefficient is overestimating the true causal effect of X  on Y  because of the 
presence of a confounder which is positively related to both  X  and Y . 
4.  The non-zero beta coefficient is entirely due to the presence of a confounder which is 
related to both  X  and Y : in fact there is no causal effect of  X  on Y . 
5.  The beta coefficient is non-zero because of a causal effect of Y  on  X , not of  X  on Y  
(i.e., reverse causation). 
 
In other words, if the interest lies in assessing ―the causal effect of  X  on Y ‖, i.e., the effect that 
would be observed if one could intervene and change someone’s  X  level by one unit, leaving other 
characteristics unchanged, no definitive conclusion can be drawn from such an analysis. We shall see 
below, illustrated in the context described by Figure 1, how the method of instrumental variables can 
help in this regard. 
A linear model (consistent with Figure 1) is given by:  
U X Y 1 1 1        
where  1   is  the causal effect of  X  on Y and where  U 1   plays the role of the error term, U  being 
some  unobserved  confounder.  Whenever X  is  correlated  with  the  error  term  (see  Figure  1),  the 
expectation of the least squares estimate of the slope in this model, which we denote by
LS
1  , will be 
different from  1  . 
The method of instrumental variables has been proposed to correct for the bias of the least squares 
estimate. For this, we need to have at our disposal an ―instrumental variable‖, or instrument Z , for the 
time being continuous or binary, satisfying the following conditions: (1) Z is correlated with X, (2) Z is 
independent from U , and (3) Z  and Y  are independent given  X  and U . Note that the former of these 
conditions is verifiable from the data, whereas the latter two are largely not. 
A second linear model (consistent with Figure 1) is then as follows: 
U Z X 2 2 2        
where  U 2   plays the role of the error term in the model. Since Z  is by assumption uncorrelated with 
this error term, the coefficients of this second model are estimated without bias by least squares. Note 
that the first model can be rewritten as: 
     U   2 1 1 2 1 2 1 1              Z Y  
Denoting  2 1 1 3       ,  2 1 3      and  2 1 1 3       , we obtain hence a third linear model: Int. J. Environ. Res. Public Health 2010, 7                 
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U Z Y 3 3 3        
where  U 3   is  the  error  term.  Since  Z  is  by  assumption  uncorrelated  with  this  error  term,  the 
coefficients of this third model are also estimated without bias by least squares.  
At  the  end,  the  parameters  of  the  first  model  can  be  consistently  estimated  using  relationships 
2 1 3 1        and  2 3 1     , the denominator  2   being non zero by assumption. In particular, the 
instrumental variable (IV) estimate of the causal effect 1   in the first model is the quotient of the two 
least  squares  estimates  of  slope  parameters 3  and  2   in  the  third  and  second  models.  Since  the 
expectation of a quotient of two estimates is asymptotically equal to the quotient of the expectations of 
these estimates, the IV estimates are asymptotically unbiased, but they may be biased in finite samples. 
Asymptotically, the IV estimates are normally distributed and explicit formulae for the standard 
errors are available, enabling to calculate confidence intervals and to test for the nullity of the causal 
effect  1   in the first model (as calculated e.g., with the ivregress 2sls command implemented in Stata 
10.0). The standard error of the estimates will depend, among others, on the percentage of explained 
variance in the second model (itself related to the percentage of explained variance in the third model). 
If this percentage is low, the instrument is said to be weak, the standard errors will be large and the test 
above  will  have  low  power.  Moreover,  the  bias  of  the  IV  estimates  is  typically  larger,  and  the 
asymptotic  normal  distribution  of  the  IV  estimates  may  be  a  poor  approximation  to  the  true 
distribution, when the instrument is weak, the inference being then unreliable [17]. In practice, an 
instrument is said to be weak if the F-statistics for testing the nullity of parameter  2   in the second 
model is inferior to 10 [18]. 
Another  equivalent  way  to  calculate  the IV  estimates  (but  without  their  standard  errors!)  is  to 
perform a ―two-stage least squares‖, regressing  X  on Z  in  a  first  stage (this is the second model 
above),  and  regressing Y  on  the  obtained  fitted  values    Z X ˆ  in  a  second  stage.  The  method  of 
instrumental  variables  can  be  readily  extended  to  the  case  of  several  instrumental  variables  (and 
therefore to the case of a qualitative instrument), which may be useful to improve the precision of the 
instrumental  variable  estimate.  One  can  also  adjust  for  additional  covariates  in  each  of  the  
above models.  
In addition to test for the nullity of the causal effect  1  , one may also  test for the absence of 
correlation between  X  and the error term in the first model, implying the equality of the parameters 
1   and 
LS
1  ,  using  the  Durbin-Wu-Hausman  test.  This  may  be  of  some  interest  when  comparing 
several candidate models which may have generated the data (see the simulations below). 
 
4. Simulations and Example 
 
To illustrate that the method of instrumental variable is effective,  we simulated data from five 
models consistent with the five above-mentioned interpretations (Table 1). In each case, we simulated 
an instrument Z  satisfying the conditions. For simplicity, we took all intercepts in these models to be 
0, all slopes to be 1, and the variables which were generated at each step were taken to be N(0,1), i.e., 
normally distributed with mean 0 and variance 1.  Int. J. Environ. Res. Public Health 2010, 7                 
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Table 1. Description of the five models used for the simulations in Section 4. 
Model  Step 1  Step 2  Step 3  Step 4  Step 5 
1. Causal effect of X on 
Y 
Z = 
N(0,1) 
X = 
Z+N(0,1) 
Y = 
X+N(0,1) 
   
2. Causal effect of X on 
Y and measurement errors 
on X and Y 
Z = 
N(0,1) 
Xtrue = 
Z+N(0,1) 
Ytrue = 
Xtrue+N(0,1) 
X = 
Xtrue+N(0,1) 
Y = 
Ytrue+N(0,1) 
3. Causal effect of X on 
Y and presence of a 
confounder 
Z = 
N(0,1) 
U = 
N(0,1) 
X = 
Z+U+N(0,1) 
Y = 
X+U+N(0,1) 
 
4. No causal effect 
between X and Y and 
presence of a confounder 
Z = 
N(0,1) 
U = 
N(0,1) 
X = 
Z+U+N(0,1) 
Y = 
U+N(0,1) 
 
5. Causal effect of Y on 
X (reverse causation) 
Z = 
N(0,1) 
Y = 
N(0,1) 
X = 
Z+Y+N(0,1) 
   
 
The causal effect of  X  on Y  that we are looking for is 1 1    under the first three models, and is 
0 1    under the last two models. Boxplots of the least squares (LS) estimates and of the instrumental 
variable (IV) estimates of parameter  1   obtained from 1,000 samples of size n = 100 under each of the 
five models are shown on the top panel of Figure 2. The LS estimate is unbiased under the first model, 
is consistently too small under the second model, and is consistently too large under the last three 
models.  By  contrast,  the IV  estimate  is almost  unbiased  under  each  of  the  five  models,  which  is 
actually remarkable. One can also notice that the IV estimate shows a higher variability than the LS 
estimate, which is the price to pay for correcting the bias of the latter. The Durbin-Wu-Hausman test 
was significant in 4.1% (which was close to the nominal 5% level) of the samples generated from the 
first model, for which 1   = 
LS
1   holds, in 66% of the samples generated from the second model, for 
which 1   > 
LS
1   holds, and in 88%, 90% and 100% from the samples generated respectively from the 
third, fourth and fifth models, for which 1  <
LS
1   holds. 
To provide an idea of what may happen when using a weak instrument, we considered the same five 
models, but the slopes involving Z  were set to 0.25 (instead of 1) in each model. In addition, we 
reduced the sample size to n = 25. Under that setting, the F-statistic in the first stage regression was 
smaller than 10 in more than 95% of the generated samples. Boxplots of the estimates obtained from 
1,000 samples are shown on the bottom panel of Figure 2. One can see that the variance of the IV 
estimates dramatically increased (compared to the top panel), while some non-negligible bias appeared.  Int. J. Environ. Res. Public Health 2010, 7                 
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Figure 2. Results of simulations based on 1,000 samples under each of the five models 
described in Table 1, using (a) a strong instrument and n = 100 and (b) a weak instrument 
and n = 25. Shown are boxplots of the 1,000 least squares estimates (LS1, LS2, LS3, LS4, 
LS5, red boxes) and of the 1,000 instrumental variable estimates (IV1, IV2, IV3, IV4, IV5, 
green boxes) of the causal effect. The true causal effect to be estimated was  1 1    (solid 
horizontal line) for the first three models, and  0 1    (dashed horizontal line) for the last 
two models. 
 
We next provide an example with real data to illustrate that the method of instrumental variable is 
able  to  correct  for  the  bias  of  least  squares  in  a  case  of  reverse  causation.  We  used  the  1,268 
participants  of the population-based CoLaus  study  [19], who reported that they consumed alcohol 
regularly and who had available data for genetic markers located with the gammaglutamyl transferase 1 
(GGT1) gene as well as circulating GGT levels ( X ). CoLaus participants have been genotyped using 
the Affymetrix 500 K chip, alcohol consumption was assessed using a standardized questionnaire and Int. J. Environ. Res. Public Health 2010, 7                 
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coded in units of alcohol per week, and GGT levels were measured using standard procedures as 
previously described [19]. As we were interested in exploring an example of reverse causation, we 
chose Y  to be the reported alcohol consumption and tested whether circulating GGT ( X ) could cause 
alcohol consumption (which we know is the opposite of the reality) using the best GGT1 marker as our 
instrument  ( Z ).  Rs2017869  explained  1.12%  of  circulating  GGT  levels. The  parameter  1   was 
estimated using least squares and the method of instrumental variables (the latter with the ivregress 
2sls command implemented in Stata 10.0). The LS estimate (95%CI) was 5.53 (4.73;6.33) mmol/L per 
risk allele. The IV estimate (95%CI) was −4.60 (−13.82; 4.63) mmol/L per risk allele, which was 
significantly  different  from  the  LS  estimate  in  a  Durbin-Wu-Hausman  test  (P  =  0.03),  and  not 
significantly  different  from  zero.  Thus,  while  the  result  provided  by  least  squares  was  highly 
significant,  the  instrumental  variable  approach  did  not  show  any  evidence  for  a  positive  causal 
association of GGT on alcohol consumption.  
 
5. Review of Observational Studies Using Mendelian Randomization 
 
We  searched  MEDLINE  using  the  following  « Mendelian  randomization»  OR  ―Mendelian 
randomisation‖, which retrieved 99 citations (January 13, 2009). We acknowledge that this search 
strategy might not have retrieved all publications using the concept of Mendelian randomization, but it 
should provide a good overview of what has been published. The aim was to identify original articles 
reporting results from an observational study using a Mendelian randomization approach. We also 
searched references from review papers and original articles, as well as citations of these papers.  
We identified 23 studies with a dichotomous trait as the outcome of interest (Table 2) and 15 studies 
with a continuous trait as the outcome of interest (Table 3). Considering that the instrumental variable 
approach has been introduced, and is well understood, for a continuous outcome, it was a bit of a 
surprise to find that a majority of studies in fact applied this method to a dichotomous outcome (using 
non-linear models and odds-ratios to quantify the associations, for which the method has not been quite 
validated, see also the next section). Thirteen out of 23 studies focusing on binary outcomes (Table 2) 
reported results compatible with a causal association. Most studies were in the field of cardiovascular 
epidemiology and cancer epidemiology. For continuous outcomes (Table 3), half of studies reported 
some evidence for causality and most studies were in the field of cardiovascular epidemiology. Most 
instruments reported in these studies were weak (Figure 3). We also found many studies that claimed 
to  use  a  Mendelian  randomization  approach  although  they  only  analyzed  the  genotype-outcome 
association, hence focusing on hypothesis testing (i.e., to confirm or disprove causality). Yet, what is of 
interest in the Mendelian randomization approach is to estimate the causal effect of  X , the modifiable 
factor, on Y and not simply the association between Z  and Y .  Int. J. Environ. Res. Public Health 2010, 7                 
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Table  2.  Literature  review  for  dichotomous  outcomes  analyzed  using  a  Mendelian 
randomization approach. 
Outcome (Y)  Gene   Variant(s) (Z)  Risk factor (X)  Causality*  Reference 
Cardiovascular epidemiology           
  Type 2 diabetes  SHBG  rs1799941  SHBG  +  [20] 
  Type 2 diabetes  SHBG  rs6257, rs6259  SHBG  +  [21] 
  Type 2 diabetes  BCMO1  rs6564851  β-carotene  ─  [22] 
  Type 2 diabetes  MIF  rs1007888  MIF  +  [23] 
- Coronary artery disease  LDLR  rs2228671  LDL-cholesterol    [24] 
  Coronary heart disease  PCSK9  Y142X, C679X  LDL  +  [25] 
  Coronary heart disease  CRP  rs1130864  CRP  ─  [26] 
  Coronary heart disease  CRP  rs7553007  CRP  ─  [27] 
  Myocardial infarction  CRP  rs1130864  CRP  ─  [28] 
  Myocardial infarction  LPA  KIV-2 (CNV)  Lp(a)  +  [29] 
  Myocardial infarction  FGB  -148C/T  fibrinogen  ─  [30] 
-Stroke  MTHFR  C677T  homocysteine  +  [31] 
  Hypertension  CRP  rs1800947,  CRP  ─  [32] 
  Metabolic syndrome  LCT  rs4988235 (-13910-C/T)  Milk consumption  +  [33] 
  Hypertriglyceridemia  RBP4  rs3758538  RBP4  ─  [34] 
Cancer epidemiology           
  Cancer  APOE  E2, E3, E4  cholesterol  ─  [35] 
  Head and neck cancer  ALDH2  rs671  Alcohol consumption  +  [10] 
  Oesophageal cancer  ALDH2  rs671  Alcohol consumption  +  [9] 
  Lung or kidney cancer  FTO  rs9939609  BMI  +  [36] 
Other topics           
  Polycystic ovary syndrome  IRS-1  Gly972Arg  Insulin  +  [37] 
  Depression  PON1  rs662  PON1 activity   ─  [38] 
  Stillbirth  CYP1A2, 
NAT2, GSTA1 
slow/fast metabolizers  caffeine  +  [39] 
  Cataract  FTO  rs9939609  BMI  +  [40] 
*  + means evidence for causality; ─  means no evidence for causality. SHBG, sex hormone binding protein; 
LDL, low density lipoprotein; CRP, C-reactive protein; Lp(a), lipoprotein a; RBP4, retinol binding protein 4; 
BMI, body mass index; PON1, paraoxonase 1 Gene symbols: SHBG, sex hormone-binding globulin; PCSK9, 
proprotein  convertase  subtilisin/kexin  type  9.  CRP,  C-reactive  protein;  LPA,  lipoprotein,  Lp(a);  FGB, 
fibrinogen  beta  chain;  LCT,  lactase;  RBP4,  retinol  binding  protein  4;  APOE,  apolipoprotein  E; ALDH2, 
aldehyde  dehydrogenase  2  family  (mitochondrial);  FTO,  fat  mass  and  obesity  associated;  IRS-1,  insulin 
receptor substrate 1; PON1, paraoxonase 1; CYP1A2, cytochrome P450, family 1, subfamily A, polypeptide 
2; NAT2, N-acetyltransferase 2 (arylamine N-acetyltransferase); GSTA1, glutathione S-transferase alpha 1. 
MIF, macrophage inhibitory factor; MTHFR, methylene tetrahydrofolate reductase;  BCMO1, beta-carotene 
15,15’-monooxygenase 1. 
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Table  3.  Literature  review  for  continuous  outcomes  analyzed  using  a  Mendelian 
randomization approach.  
Outcome (Y)  Gene (s)  Variant(s) (Z)  Risk factor (X)  Causality*  Reference 
Metabolic traits (insulin, lipids, etc)  FTO  rs9939609  BMI  +  [41] 
BMI  CRP  rs1800947, rs1205  CRP  ─  [42] 
BMI  CRP, 
LEPR 
rs7553007 
rs1805096 
CRP  +  [43] 
BMI, blood pressure, triglycerides, 
HDL, waist-to-hip ratio, HOMA-R 
CRP  rs1800947, rs1130864, rs1205  CRP  ─  [44] 
Blood pressure  MC4R 
FTO 
rs17782313 rs9939609  BMI  +  [45] 
Blood pressure  CRP  rs1800947,  CRP  ─  [32] 
Bone mass  MC4R 
FTO 
rs17782313 
rs9939609 
adiposity  +  [46] 
Bone mass density, bone fractures  LCT  rs4988235 (-13910-C/T)  Calcium intake  +  [47] 
HbA1c  CRP  rs1130864, rs1205, rs3093077  CRP  ─  [48] 
Carotid-intima media thickness  CRP  rs1130864, rs1205, rs3093077  CRP  ─  [49] 
Carotid-intima media thickness  CRP  rs 2794521, rs3091244, 
rs1800947, rs1130864, rs1205 
CRP  ─  [50] 
Carotid-intima media thickness  FTO  rs9939609  BMI  +  [51] 
Serum leptin  CRP  rs 2794521, rs3091244, 
rs1800947, rs1130864, rs1205 
CRP  ─  [52] 
Lung function  CRP  rs1205, rs1800947  CRP  +  [53] 
Physical functioning  IL-18  rs5744256  IL-18  +  [54] 
BMI, body mass index. CRP, C-reactive protein. IL-18, interleukin 18. LEPR, leptin receptor. For other gene 
symbols, see Table 2 legend. 
Figure  3.  Type  and  frequency  of  genetic  instruments  in  Mendelian  randomization.  R
2 
represent  the  proportion  of  variance  of  X  explained  by  Z .  Percentage  in  parentheses 
represent R
2 value for the first linear regression in 2-stage least squares regression models.  
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6. Some Limitations of Mendelian Randomization 
 
In order to use Mendelian randomization to infer causality in observational epidemiology, numerous 
conditions need to be fulfilled [13,55-57]. A major limitation of this approach is that it is difficult, in 
practice, to meet al.l these conditions for a given risk factor—outcome association. To fulfill the first 
condition,  Z  and  X  should  be  correlated  (genetic  instruments  for  common  complex  diseases  are 
typically  quite  weak).  This  indirectly implies  that there  is  some  level  of  allelic  homogeneity  (i.e., 
common  variants  rather  than  rare  variants).  Note  that  for  many  exposures,  no  suitable  genetic 
instrument is available. The second and third conditions are the problematic ones. They state that Z  is 
(marginally)  independent  from  all  potential  confounders U ,  and  that  Z  and  Y  are  independent 
conditionally on  X  and U  [57]. In an excellent introduction to Mendelian randomization, Didelez and 
Sheehan [58] wrote that ―if we know a gene closely linked to the phenotype without direct effect on the 
disease, it can often be reasonably assumed that the gene is not itself associated with any confounding 
factors‖. See however Section 7 of that paper for situations in which these conditions are not satisfied. 
Mendel’s  second  law  (i.e.,  the  law  of  independent  assortment  of  alleles  at  the  time  of  gamete 
formation) is not always true in that genetic variants located on the same chromosome, particularly for 
close loci, do not segregate independently (i.e., they are linked), as detailed in Lawlor et al. [13]. At the 
population  level,  such  physical  linkage  patterns  result  in  linkage  disequilibrium,  i.e.,  correlations 
between alleles at nearly loci. In genetic epidemiology, the second condition implies, among others, 
that there should be no confounding due to linkage disequilibrium (i.e., instrument Z  should not be 
correlated with other genetic variants having an effect on the outcome of interest, Y ) [13]. However, 
the instrument Z  does not necessarily need to be causally associated with X, in that another genetic 
variant  associated  to  both  Z  and  X  might  be  the  true  causal  variant [13].  Similarly,  population 
stratification, i.e., the existence of population subgroups with different allele frequencies and outcome 
distributions,  may  violate  this  second  condition  as  well.  In  the  Mendelian  randomization  context, 
confounding may exist if the subgroups (these often correspond to ethnic groups) are associated to both 
Z  and Y [13]. 
Also, there should be no pleiotropy, (i.e., Z  having multiple effects, which do not pass through  X ). 
This is however only a problem if the other functions of Z  are associated to Y  [13]. There should be 
no  canalization  (also  called  developmental  compensation),  which  corresponds  to  a  functional 
adaptation  to  a  specific  genotype  influencing  the  expected  genotype-disease  association  [13].  For 
instance, a gene expressed during fetal development may enhance the expression of other genes having 
compensatory effects on the outcome [13]. For most genetic variants involved in complex traits, the 
effect  size  is  small  and  we  do  not  know  if  such  modifications  would  lead  to  developmental 
compensation. Furthermore, there should be no segregation distortion at the locus of interest. Although 
unlikely,  it  has  been  reported  that  some  loci  in  the  human  genome  show  some  evidence  of  such 
distortion [59]. Of course, there should be no selective survival due to the genetic variant of interest. 
Considering that the randomization occurred many years before the analysis is conducted, if a specific 
genotype were associated with increased early mortality, the genotypic distribution at the time of the 
study  might  not  reflect  the  initial  distribution.  For  instance,  the C677T  MTHFR  variant  has  been 
associated with fetal viability [60,61]. And finally, although this has rarely been assessed so far, there Int. J. Environ. Res. Public Health 2010, 7                 
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should be no parent-of-origin effect (i.e., the effect of the paternally transmitted allele should be the 
same as the effect of the maternally transmitted allele). 
A practical condition is that there should be enough data to establish reliable genotype-intermediate 
phenotype, or genotype-outcome, associations. In our literature review, we observed that for many 
publications, estimates for these two associations came from different studies. Whenever independent 
studies have analyzed these two relationships, separate meta-analyses can be conducted. For studies 
having assessed both relationships, a multivariate model is needed in order to take into account the 
correlation in the genotype–phenotype and genotype–disease associations. Minelli et al. proposed a 
method to use meta-analysis results in a multivariate Mendelian randomization approach [62,63]. Note 
that their approach is based on odds ratios (see below). According to some authors, the advantage of 
using the same study (or studies) to estimate both associations include (1) being in a better position to 
examine  whether  or  not  the  assumptions  underlying  the  instrumental  variable  method  have  been 
violated or not and (2) having greater precision [13].  
Many  of  the  studies  we  identified  applied  a  Mendelian  randomization  approach  with  a  binary 
outcome. While econometricians have proposed instrumental variables methods for binary outcomes 
(see Lawlor et al. [13] for a nice review), the generalization of instrumental variables to non-linear 
systems is not at all straightforward  and may require additional assumptions [13,58]. One possibility is 
to build a linear model using risk differences, instead of risk ratios [64]. Another is to use a latent 
model, in which the underlying outcome variable is assumed to be continuous and the observed binary 
outcome reflects whether or not a specific threshold has been reached (e.g., probit models). Log-linear 
and logistic structural mean models for binary outcomes were also developed [65,66], where it was not 
possible to avoid some bias. Palmer et al. [67] proposed an adjusted IV estimate to reduce the bias of 
the classical IV estimate applied to a binary outcome, but admitted to ignore whether, and under what 
conditions,  the  estimated  parameter  had  a  strictly  causal  interpretation.  They  also  noted  that 
―instrumental variable theory has not been fully generalized to non-linear situations‖. Finally, one may 
obtain bounds on the causal effect using a non-parametric method whenever the instrument, the risk 
factor  and  the  disease  are  all  categorical  [58].  Note  that  none  of  the  published  studies  of  binary 
outcomes we found used these methods.  
7. Conclusions 
The Mendelian randomization approach in observational epidemiology is a valuable tool that has 
taken  a  new  dimension  in  the  post-genomic  era  and  is  being  used  increasingly.  This  approach 
conceptually  relies  on  an  instrumental  variable  approach.  There  have  been  some  successes  of  the 
Mendelian  randomization  approach  to  help  unraveling  causal  relationships  in  observational 
epidemiology. Examples are the recently published evidence for the causal role of body mass index on 
blood  pressure  [45]  or  accumulating  evidence  against  the  causal  role  of  CRP  in  coronary  heart  
disease [26-28] or atherosclerosis [49,50]. This method however suffers from several limiting factors. 
First, most genetic variants (Z ) only explain a very small proportion of variance of the phenotype of 
interest ( X ). This implies that very large sample sizes are usually needed (>10,000) to reach sufficient 
power. Second, for many associations of interest, it is not possible to find an appropriate instrumental 
variable.  However,  as  many  more  instruments  are  being  discovered,  the  prospects  are  improving. Int. J. Environ. Res. Public Health 2010, 7                 
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Third, the success of this method heavily rests on the existence of allelic homogeneity, i.e., a common 
causal allele is shared by many individuals. Fourth, whereas analytic methods have been described for 
continuous outcomes, it is unclear to what extent these methods also apply to dichotomous outcomes. 
Considering the clear interest for epidemiologists to apply this concept for dichotomous outcomes such 
as  diseases,  it  would  be  important,  and  even  urgent,  to  clarify  the  issues  on  the  validity  of  the 
instrumental variable approach in this context. More methodological development is needed before the 
instrumental variable approach can be confidently used for binary outcomes. 
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